Kairos Pharma Ltd. to Showcase Oncology Innovations at H.C. Wainwright Global Investment Conference

Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company specializing in cancer therapeutics, has announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference. The event, taking place from September 8 to 10, 2025, at the Lotte New York Palace Hotel in New York City, will feature Kairos Pharma in one-on-one meetings and a virtual presentation accessible via kairospharma.com.

The company's focus on overcoming drug resistance and immune suppression in cancer through structural biology positions it as a key player in oncology research. Its lead candidate, ENV105, targets CD105, a protein associated with resistance to various cancer treatments. ENV105 is currently undergoing Phase 2 clinical trials for castrate-resistant prostate cancer and Phase 1 trials for lung cancer, addressing critical gaps in cancer treatment options.

This presentation at the H.C. Wainwright conference underscores Kairos Pharma's commitment to advancing cancer therapeutics and its potential to revolutionize treatment paradigms for patients with limited options. The opportunity to engage with investors and the broader financial community at such a prestigious event highlights the significance of Kairos Pharma's research and development efforts in the biopharmaceutical sector.